43 Results for "

chronic obstructive lung disease

" in MedChemExpress (MCE) Product Catalog:
Products (43)

43 Results for "chronic obstructive lung disease" in MCE Product Catalog:

23
23 Publications Verification
Cat. No.: HY-101140
CAS No.: 1799974-70-1
Purity:  98.67%
Research Areas:  

Inflammation/Immunology

KI696 is a selective KEAP1/NRF2 protein-protein interaction inhibitor with a human Kd value of 1.3 nM. KI696 acts by competitively occupying the NRF2-binding pocket of the KEAP1 Kelch domain. KI696 blocks KEAP1-mediated ubiquitination and degradation of NRF2, promotes the translocation of NRF2 to the nucleus, activates the expression of downstream antioxidant genes, increases intracellular glutathione levels, and alleviates oxidative stress-induced cell damage and inflammatory cell infiltration in the lungs. KI696 reduces ozone-induced pulmonary oxidative damage and inflammatory cell accumulation in rats, and upregulates pulmonary antioxidant genes. KI696 can be used in research related to chronic obstructive pulmonary disease, oxidative stress and inflammation .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-14299
CAS No.: 312753-06-3
Purity:  99.98%
Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-14299A
CAS No.: 753498-25-8
Purity:  99.82%
Synonyms: QAB149
Indacaterol maleate (QAB149) is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol maleate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol maleate can also be used in cardiovascular disease research .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-N2593
CAS No.: 32507-66-7
Isorhapontigenin is an orally active dietary polyphenol. Isorhapontigenin acts as a potent antioxidant that reduces the production of reactive oxygen species (ROS). Isorhapontigenin promotes the binding of JUN to the AP-1 site on the SESN2 promoter, induces SESN2 transcription, triggers MAPK8-dependent JUN activation, and upregulates the expression of PPAR-α, PGC-1α and CPT-1A to facilitate fatty acid oxidation. Isorhapontigenin induces autophagy, apoptosis and preadipocyte differentiation; it inhibits tumor growth, cell invasion, NF-κB transcriptional activity, the PI3K/Akt signaling pathway, STAT1 phosphorylation and MMP-2 expression. Isorhapontigenin alleviates oxidative stress, inflammatory cytokine release and triglyceride accumulation; it increases intracellular ATP levels and promotes Nrf2 nuclear translocation. Isorhapontigenin improves insulin sensitivity in adipose tissue and glucose tolerance, and reduces postprandial blood glucose, insulin and free fatty acid levels. Isorhapontigenin is applicable to research on bladder cancer, liver injury, chronic obstructive pulmonary disease, acute lung injury and type 2 diabetes .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-112726
CAS No.: 1478364-68-9
Purity:  98.79%
Synonyms: BI-1467335
Target:  

VAP-1 MMP

PXS-4728A is an orally active, selective VAP-1/SSAO inhibitor with an IC50 of 5 nM and a Ki of 175 nM. PXS-4728A inhibits the expression of MMP-9. It reduces cell rolling, adhesion and migration, decreases cell infiltration levels, pro-inflammatory cytokines, chemokines and collagen deposition, and improves pulmonary function. PXS-4728A reduces the formation and progression of atherosclerotic plaques, and decreases blood lipid and blood glucose levels as well as body weight gain. PXS-4728A can be used in research related to chronic obstructive pulmonary disease, cystic fibrosis, acute pulmonary inflammation, acute lung injury, bronchiolitis obliterans syndrome, rhinovirus-exacerbated asthma, sepsis, Klebsiella pneumoniae pulmonary infection and atherosclerosis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-B0460
CAS No.: 411207-31-3
Synonyms: BA-679 BR monohydrate
Target:  

mAChR

Research Areas:  

Inflammation/Immunology

Tiotropium bromide monohydrate (BA-679 BR monohydrate) is a long-acting anticholinergic bronchodilator. Tiotropium bromide monohydrate blocks the action of acetylcholine at muscarinic M1, M2, and M3 receptors, prevents bronchoconstriction, and dilates bronchial airways. Tiotropium bromide monohydrate is applicable to research related to chronic obstructive pulmonary disease and asthma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-119708
CAS No.: 1884461-72-6
Purity:  99.70%
Synonyms: RPL-554
Ensifentrine (RPL-554) is an inhaled dual inhibitor of PDE3 and PDE4 with IC50s of 0.4 nM and 1479 nM, respectively. Ensifentrine blocks PDE3 and PDE4 enzymes, thereby increasing the levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in lung cells, dilating the bronchi, and inhibiting the activation and migration of inflammatory cells. Ensifentrine can be used in the research of chronic obstructive pulmonary disease (COPD) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-148096
CAS No.: 1637532-68-3
Purity:  99.81%
Target:  

STAT

Research Areas:  

Inflammation/Immunology Cancer

STAT6-IN-1 (Compound 19a) is a STAT6 inhibitor with a high affinity for the SH2 domain of STAT6 (IC50=0.028 µM). STAT6-IN-1 can be used in studies of allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease or cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-121246
CAS No.: 848353-85-5
Purity:  99.78%
Synonyms: AKF-PD
Fluorofenidone (AKF-PD) is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-136239
CAS No.: 5534-18-9
Purity:  99.76%
Synonyms: Beclomethasone-17-monopropionate; 17-BMP
Beclomethasone 17-propionate (Beclomethasone-17-monopropionate), an active metabolite of Beclomethasone dipropionate (HY-13571), is a glucocorticoid receptor (GR) agonist. Beclomethasone 17-propionate exhibits greater affinity for GR than Beclomethasone dipropionate. Beclomethasone 17-propionate effectively suppresses cytokine production in chronic obstructive pulmonary disease (COPD) lung macrophages .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-137976
CAS No.: 151937-76-7
Purity:  99.2%
Synonyms: Penequinine hydrochloride
Penehyclidine (Penequinine) hydrochloride, a anticholinergic agent, is a selective antagonist of M1 and M3 receptors. Penehyclidine hydrochloride activates NF-kβ in lung tissue and inhibits the release of inflammatory factors. Penehyclidine hydrochloride can alleviate the pulmonary inflammatory response in rats with chronic obstructive pulmonary disease (COPD) undergoing mechanical ventilation .
loading...
    loading...
Cat. No.: HY-P99244
CAS No.: 1007106-86-6
Synonyms: ILV 094
Fezakinumab (ILV 094) is an anti-IL-22 monoclonal antibody. Fezakinumab inhibits IL-22 signal transduction, and regulates the JAK1/STAT3 pathway as well as apoptotic proteins. Fezakinumab alleviates airway remodeling, alveolar enlargement and inflammatory cell infiltration in lung tissues. Fezakinumab reduces the levels of neutrophils, lymphocytes, eosinophils and macrophages in lung tissues. Fezakinumab can be used in the research of chronic obstructive pulmonary disease and skin diseases .
loading...
    loading...
Cat. No.: HY-148092
CAS No.: 1637532-77-4
Purity:  98.87%
Target:  

STAT

Research Areas:  

Inflammation/Immunology Cancer

PM-43I is a potent STAT6 inhibitor and can reduce STAT6 phosphorylation level. PM-43I can be used in allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease and cancer research [1].
loading...
    loading...
Cat. No.: HY-101140A
CAS No.: 1799974-69-8
Purity:  99.32%
Target:  

Drug Isomer

Research Areas:  

Inflammation/Immunology

KI696 isomer is an isomer of KI696 (HY-101140). KI696 is a selective KEAP1/NRF2 protein-protein interaction inhibitor with a human Kd value of 1.3 nM. KI696 acts by competitively occupying the NRF2-binding pocket of the KEAP1 Kelch domain. KI696 blocks KEAP1-mediated ubiquitination and degradation of NRF2, promotes the translocation of NRF2 to the nucleus, activates the expression of downstream antioxidant genes, increases intracellular glutathione levels, and alleviates oxidative stress-induced cell damage and inflammatory cell infiltration in the lungs. KI696 reduces ozone-induced pulmonary oxidative damage and inflammatory cell accumulation in rats, and upregulates pulmonary antioxidant genes. KI696 can be used in research related to chronic obstructive pulmonary disease, oxidative stress and inflammation .
loading...
    loading...
Cat. No.: HY-118177
CAS No.: 1448314-31-5
Research Areas:  

Inflammation/Immunology

Neutrophil elastase inhibitor 1 is a competitive, pseudo-reversible inhibitor of human neutrophil elastase (HNE) with an IC50 of 7 nM. Neutrophil elastase inhibitor 1 also exhibits inhibitory activity against thrombin, chymotrypsin and urokinase, with IC50 values of 1.9 μM, 66 nM and 6.6 μM, respectively. Neutrophil elastase inhibitor 1 can be used in research related to acute respiratory distress syndrome, chronic obstructive pulmonary disease and other conditions .
loading...
    loading...
Cat. No.: HY-168973
CAS No.: 1285607-08-0
Synonyms: AER-01; MUC-031
Target:  

Mucin

Research Areas:  

Inflammation/Immunology

Fexlamose (AER-01) is a thiol-modified carbohydrate agent with mucolytic property. Fexlamose cleaves disulfides to cause mucolysis. Fexlamose can be used for researchs of chronic obstructive pulmonary disease (COPD) and muco-obstructive lung diseases (MOLD) .
loading...
    loading...
Cat. No.: HY-148093
CAS No.: 1637532-83-2
Purity:  99.91%
Target:  

STAT

Research Areas:  

Inflammation/Immunology Cancer

PM-81I is a potent STAT6 inhibitor (targeting the SH2 structural domain) that effectively reduces STAT6 phosphorylation levels. PM-81I can be used in studies of allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease or cancer [1].
loading...
    loading...
Cat. No.: HY-14299AR
CAS No.: 753498-25-8
Synonyms: QAB149 (Standard)
Indacaterol (maleate) (Standard) is the analytical standard of Indacaterol (maleate). This product is intended for research and analytical applications. Indacaterol maleate (QAB149) is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol maleate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol maleate can also be used in cardiovascular disease research .
loading...
    loading...
Cat. No.: HY-14299R
CAS No.: 312753-06-3
Indacaterol (Standard) is the analytical standard of Indacaterol. This product is intended for research and analytical applications. Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research .
loading...
    loading...
Cat. No.: HY-174383
CAS No.: 2857007-03-3
Research Areas:  

Inflammation/Immunology

PDE3/4-IN-2 is a dual PDE3A and PDE4B1 inhibitor, with an IC50 of 0.13 nM against PDE3A and 50 nM against PDE4B1. PDE3/4-IN-2 exhibits higher systemic exposure and longer retention time in lung tissues in ICR mice. PDE3/4-IN-2 can be used in research on respiratory diseases such as asthma and chronic obstructive pulmonary disease, as well as autoimmune inflammation-related studies .
loading...
    loading...